Cancer rapid diagnostic test Xpert®

for womenfor tumor markerstissue

Used in conjunction with GeneXpert® technology, Xpert Breast Cancer STRAT4 simplifies breast cancer biomarker assessment through semi-automated sample preparation, automated RNA isolation, reverse transcription, amplification by real-time PCR and detection. The entire process happens within a patented cartridge-based system. The Need Breast cancer biomarker ER/PGR/HER2/Ki-67 results need to be dependable and objective Clinicians need more reliable ER/PGR/HER2/Ki-67 assessment in FFPE tumor tissues. 5% of HER2 IHC results are equivocal based upon guide line recommended classifications.1 Resolving HER2 IHC2+ equivocal results with FISH is challenging.1-4 Technical and observer variability can lead to approximately 20% inaccurate ER and PGR results. Ki-67 IHC scores deviate due to a lack of standardization. The Solution Xpert® Breast Cancer STRAT4 paves the way for a standardized, precise and reliable ER/PGR/HER2/Ki-67 mRNA assessment in less than 2 hours Xpert Breast Cancer STRAT4 delivers semi-quantitative determination of ER/PGR/HER2/Ki-67 mRNA levels in FFPE invasive breast cancer sections CYFIP1* reference gene is used for sample normalization Three controls included in each test Software report allows for objective and easy result interpretation External FFPE controls# available for identifying errors, shifts, trends and operator variabilities The Impact Xpert Breast Cancer STRAT4 standardizes reproducible ER/PGR/HER2/Ki-67 assessment Clear and accurate results empower oncologists. Enables flexibility, simplicity and random access for a streamlined workflow 24/7. Easy and fast test implementation.